Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Awakn Life Sciences Corp (AWKN.NE)

Awakn Life Sciences Corp (AWKN.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,454
  • Shares Outstanding, K 38,734
  • Annual Sales, $ 1,495 K
  • Annual Income, $ -9,143 K
  • 60-Month Beta N/A
  • Price/Sales 1.96
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AWKN.NE with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings $-0.02 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1050 +4.76%
on 02/08/24
0.1700 -35.29%
on 01/17/24
-0.0250 (-18.52%)
since 01/16/24
3-Month
0.0550 +100.00%
on 11/17/23
0.2300 -52.17%
on 11/27/23
+0.0450 (+69.23%)
since 11/16/23
52-Week
0.0550 +100.00%
on 11/17/23
0.5500 -80.00%
on 04/26/23
-0.3300 (-75.00%)
since 02/16/23

Most Recent Stories

More News
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange

Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted...

AWKNF : 0.0750 (+2.32%)
AWKN.CN : 0.0950 (unch)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Announces Conditional Approval of CSE Listing

Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers

Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US MarketToronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"),...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS

Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents Filed in US and Key International MarketsToronto, Ontario--(Newsfile...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto, Ontario--(Newsfile Corp. - November...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements

Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder

Toronto, Ontario--(Newsfile Corp. - October 31, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study

Study Confirms MDMA Is Stable on Zydis(R) ODT and Suitable for Pre-Gastric AbsorptionToronto, Ontario--(Newsfile Corp. - October 4, 2023) -  Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Provides Corporate Update

Announces Closing of Third Tranche of Private PlacementToronto, Ontario--(Newsfile Corp. - September 14, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage...

AWKNF : 0.0750 (+2.32%)
AWKN.NE : 0.1100 (-21.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people...

See More

Key Turning Points

3rd Resistance Point 0.1600
2nd Resistance Point 0.1500
1st Resistance Point 0.1300
Last Price 0.1100
1st Support Level 0.1000
2nd Support Level 0.0900
3rd Support Level 0.0700

See More

52-Week High 0.5500
Fibonacci 61.8% 0.3609
Fibonacci 50% 0.3025
Fibonacci 38.2% 0.2441
Last Price 0.1100
52-Week Low 0.0550

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar